Vivianne C Tjan-Heijnen
Overview
Explore the profile of Vivianne C Tjan-Heijnen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
662
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lommen K, Vaes N, Aarts M, van Roermund J, Schouten L, Oosterwijk E, et al.
Eur Urol Oncol
. 2019 Aug;
4(2):215-226.
PMID: 31402218
Context: The 5-yr survival of early-stage renal cell carcinoma (RCC) is approximately 93%, but once metastasised, the 5-yr survival plummets to 12%, indicating that early RCC detection is crucial to...
2.
Joosten S, Smits K, Aarts M, Melotte V, Koch A, Tjan-Heijnen V, et al.
Nat Rev Urol
. 2018 Jun;
15(7):430-451.
PMID: 29867106
Renal cell carcinoma (RCC) is characterized by an infrequent number of somatic mutations. By contrast, epigenetic aberrations are commonly found in RCC, indicating that epigenetic reprogramming is an important event...
3.
Joosten S, Deckers I, Aarts M, Hoeben A, van Roermund J, Smits K, et al.
Epigenomics
. 2017 Aug;
9(9):1243-1257.
PMID: 28803494
Aim: Despite numerous published prognostic methylation markers for renal cell carcinoma (RCC), none of these have yet changed patient management. Our aim is to systematically review and evaluate the literature...
4.
Abbema D, van Vuuren A, van den Berkmortel F, van den Akker M, Deckx L, Buntinx F, et al.
J Geriatr Oncol
. 2017 Feb;
8(3):176-184.
PMID: 28159513
Objectives: The aim of the present study was to disentangle the impact of age and that of cancer diagnosis and treatment on functional status (FS) decline in older patients with...
5.
Truin W, Roumen R, Siesling S, van der Heiden-van der Loo M, Lobbezoo D, Tjan-Heijnen V, et al.
Clin Breast Cancer
. 2016 Apr;
16(4):e75-82.
PMID: 27116948
Background: Sentinel lymph node (SLN) biopsy is the standard of care for axillary staging in invasive breast cancer. The introduction of SLN biopsy with an extensive pathology examination, in addition...
6.
Klompenhouwer E, Voogd A, den Heeten G, Strobbe L, Tjan-Heijnen V, Broeders M, et al.
Eur Radiol
. 2015 Apr;
25(10):2821-9.
PMID: 25894007
Objectives: To determine the value of adding a third reader for arbitration of discrepant screening mammography assessments. Methods: We included a consecutive series of 84,927 digital screening mammograms, double read...
7.
Aarts M, Grutters J, Peters F, Mandigers C, Dercksen M, M Stouthard J, et al.
J Clin Oncol
. 2013 Oct;
31(34):4283-9.
PMID: 24166522
Purpose: Guidelines advise primary granulocyte colony-stimulating factor (G-CSF) prophylaxis during chemotherapy if risk of febrile neutropenia (FN) is more than 20%, but this comes with considerable costs. We investigated the...
8.
Hurvitz S, Dalenc F, Campone M, ORegan R, Tjan-Heijnen V, Gligorov J, et al.
Breast Cancer Res Treat
. 2013 Oct;
141(3):437-46.
PMID: 24101324
Increased activation of the PI3K/Akt/mTOR pathway is a common factor in putative mechanisms of trastuzumab resistance, resulting in dysregulation of cell migration, growth, proliferation, and survival. Data from preclinical and...
9.
Brandao R, Veeck J, Van de Vijver K, Lindsey P, de Vries B, van Elssen C, et al.
Breast Cancer Res
. 2013 Apr;
15(2):R29.
PMID: 23566419
Introduction: Cyclooxygenase-2 (COX-2) is frequently over-expressed in primary breast cancer. In transgenic breast cancer models, over-expression of COX-2 leads to tumour formation while COX-2 inhibition exerts anti-tumour effects in breast...
10.
Cardoso F, Bischoff J, Brain E, Guerrero Zotano A, Luck H, Tjan-Heijnen V, et al.
Cancer Treat Rev
. 2012 Jul;
39(5):457-65.
PMID: 22840697
Endocrine therapy is the corner stone treatment for postmenopausal women with hormone receptor-positive metastatic breast cancer (MBC). Besides tamoxifen and many older agents, recently developed endocrine agents for the treatment...